11: Study the Impact of Number and Type of HLA Incompatibilities and Cell Dose on Outcomes of Unrelated Cord Blood Transplants for Patients with Malignant and Non-Malignant Disorders  by Gluckman, E. & Rocha, V.
10
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
IN THE TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIA (ALL) IN 126
ADULTS: IMPACT OF DONOR SOURCE ON LEUKEMIA FREE SURVIVAL
(LFS)
Kumar, Priya, Defor, Todd E., Brunstein, Claudio, Barker, Juliet N.,
Wagner, John E., Weisdorf, Daniel J., Miller, Jeffrey S., McGlave, Philip,
Slungaard, Arne, Arora, Mukta, Tomblyn, Marcie, Burns, Linda J. Blood
and Marrow Transplant Program, University of Minnesota, Minneap-
olis, MN.
White blood cell (WBC) count and speciﬁc cytogenetic abnor-
malities at diagnosis, patient age and disease status at HSCT have
previously been identiﬁed as risk factors associated with LFS in
patients with ALL. As the use of umbilical cord blood (UCB) is
relatively new, particularly for adults, we sought to evaluate the
relative impact of donor source.
In this single center study, 126 adults aged 18-61 (median 31)
years (yrs) underwent myeloablative conditioning (cyclophosph-
amide 120 mg/kg and total body irradiation 1320-1375 cGy
based regimen in 92%) followed by allogeneic HSCT. Stem cell
source was an HLA matched related donor (MRD) in 85, HLA
matched unrelated donor (URD: M) in 15, HLA mismatched
unrelated donor (URD: MM) in 14 and HLA 0-2 (A, B, DRB1)
mismatched UCB in 12. At the time of HSCT, 64 patients were
in CR1, 51 in CR2, and 11 patients in CR3; 20 patients had
T-lineage disease; 38 patients (30%) had either t (9; 22) (n 
28), t (4; 11) or t (1, 19) (n  10) with the remainder (70%)
having normal cytogenetics. WBC 30  109/L at diagnosis
was documented in 50%. Demographics, disease characteristics
at initial diagnosis and transplant variables were similar in all 4
groups except: year of transplant after 1996 and use of growth
factor for all UCB recipients.
Outcomes by donor source: As a consequence of low transplant
related mortality (TRM), overall survival (OS) and LFS were
superior after UCB transplants. In multiple regression analysis, 5
independent risk factors were signiﬁcantly associated with poorer
OS: use of URD:M (RR 3.8, 95% CI 1.1-13.8, P  0.04) and
URD:MM (RR 4.9, 95% CI, 1.3-19.1, P  0.02), CR3 at HSCT
(RR 3.0, 95% CI, 1.1-8.8, P  0.04), WBC 30  109/L (RR 2.4,
95% CI, 1.4 -4.1, P  0.01), cytomegalovirus (CMV) seropositive
recipient and donor (RR 4.0, 95% CI, 2.0-7.9, P  0.01), and 2
induction regimens to achieve initial CR (RR 2.7, 95% CI, 1.2-5.9,
P  0.01). Patients who developed grade II-IV acute graft versus
host disease (GVHD) had signiﬁcantly lower mortality rates (RR
0.4, 95% CI, 0.2-0.7, P  0.01). There was no impact on OS by
year of transplant or use of growth factor. Variables associated with
poor LFS were identical to those for OS, and GVHD was again
associated with improved LFS.
These results support the use of UCB as an alternative stem cell
source for adults with ALL, with results comparable to outcomes
observed with MRDs. In addition, GVHD is associated with im-
proved LFS suggesting a signiﬁcant graft versus leukemia effect
with all donor graft sources.
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STUDY THE IMPACT OF NUMBER AND TYPE OF HLA INCOMPATIBILI-
TIES AND CELL DOSE ON OUTCOMES OF UNRELATED CORD BLOOD
TRANSPLANTS FOR PATIENTS WITH MALIGNANT AND NON-MALIG-
NANT DISORDERS
Gluckman, E., Rocha, V. for Eurocord. Hospital Saint Louis, Paris,
France.
The objective was to study the interactions between HLA type
and number and cell dose infused with the outcomes of unrelated
cord blood transplants in order to produce prognosis indices and
determine criteria of donor choice.
One thousand patients with hematological malignancies were
analyzed. The results show that cell dose is the most important
factor for engraftment and transplant related mortality (Table 1). A
minimum of 3  107 nucleated cells/kg at collection and 2 
107/kg at infusion must be obtained. HLA mismatches increase the
risk of engraftment delays, transplant related mortality and chronic
GVH; it decreases the risk of relapse resulting in an absence of the
role of HLA mismatches for survival. The type of HLA mis-
matches did not inﬂuence the outcome but matching for DRB1
improves outcome. Most importantly, increasing cell dose abro-
gates the inﬂuence of HLA mismatches (Table 2).
In 268 patients with non malignant diseases, requirements for
cell dose and HLA matching were different in non malignant
diseases compared to malignant diseases. In non malignant dis-
eases, cell dose is higher at 4.9  107/kg at collection and 3.5 
107/kg at infusion. HLA mismatches play a major role for engraft-
ment, survival and GVH. It is partially abrogated by increasing cell
dose. Two HLA DRB1 mismatches resulted in an adverse outcome
(Table 3).
Conclusions:
● Our results show that requirements for cell dose and HLA
matching are different in malignant and non malignant dis-
eases.
● In non malignant disease, cell dose is higher with 4.9 107/kg
at collection and 3.5  107 NC/kg at collection while it is
at 3.  107/kg at collection and 2  107 NC/kg in malignant
diseases. This difference is probably due to the pretransplant
chemotherapy in malignant diseases.
● HLA mismatches play a major role for engraftment and sur-
vival in non malignant diseases while in malignant disease it
has a beneﬁcial role for preventing leukemic relapse resulting
in an absence of effect on leukemia free survival.
● HLA mismatches can be partially overcome by increasing cell
dose.
● Matching for class II is better than for class I.
Table 1. Summary of Outcomes in Umbilical Cord Blood Transplants
From Eurocord Registry
MRD URD:M URD:MM UCB P
n 85 15 14 12
Median follow-up (y) 9.3 3.5 7.2 1.2
OS 1 yr % (95% CI) 41 (31-52) 33 (9-57) 14 (0-33) 75 (51-100) 0.02
LFS 1 yr % (95% CI) 35 (25-45) 27 (4-49) 14 (0-33) 67 (40-93) 0.03
Relapse 1 yr % (95%
CI) 21 (12-30) 20 (0-40) 0 8 (0-23) 0.22
TRM 1 yr % (95% CI) 44 (33-55) 53 (27-79) 86 (57-100) 25 (1-49) <0.01
Table 2. Interaction between HLA Mismatches, Number of Cells
and Outcomes in Unrelated Cord Blood Transplants for Malignant
Diseases
Number of
HLA MM
0-1 vs 2 vs 3-4
Type of HLA
MM Class I vs II
Interaction with
Number of Cells
PMN
engraftment
Less Same Worse 3-4 mismatches and
<3  107 NC/kg
Platelet
engraftment
Less Same Worse 3-4 mismatches and
<3  107 NC/kg
TRM More More 2 DR MM Worse 3-4 mismatches and
<3  107 NC/kg
aGVHD More More 2 DR MM Same
cGVHD More Same Decreased <MM and >cells
Relapse Less Less 2 DR aMM Increased <MM and >cells
LFS, OS Same Same Decreased >MM and <cells
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UMBILICAL CORD BLOOD TRANSPLANTATION FOR TRANSFUSION-
DEPENDENT THALASSEMIA AND SICKLE CELL DISEASE
Walters, Mark. Children’s Hospital Oakland Research Institute, Oak-
land, CA.
Sickle cell anemia and -thalassemia major are clinically signiﬁ-
cant hereditary anemias that elicit world-wide attention due to the
frequency and severity of these disorders. Historically, most chil-
dren who inherited these disorders died in the ﬁrst decade of life.
In the contemporary era, however, supportive care has extended
lifespan through the 5th decade of life and beyond, with survival
through early adulthood now indistinguishable from those unaf-
fected by these disorders. As a result, chronic health impairments
that signiﬁcantly reduce the quality of life have become the prin-
cipal challenge in -thalassemia major and sickle cell anemia.
Thus, the application of hematopoietic cell transplantation and its
inherent risk of mortality in the short-term must be balanced by
the beneﬁt of survival without the burden of chronic illness in the
long-term. Toward this end, the development of umbilical cord
blood transplantation (UCBT) represents a signiﬁcant advance due
to its association with a lower risk of graft-versus-host disease
(GVHD), the leading cause of mortality and morbidity after HCT
for hemoglobinopathies. We have observed outcomes after UCBT
that are identical to earlier results of bone marrow transplantation
for hemoglobinopathies. In our multi-center series of patients
treated by HLA-identical sibling UCBT, 26 of 29 (90%) survive,
and 25 (86%) survive disease-free. Overall, the Kaplan-Meier
probabilities of survival and event-free survival after sibling UCBT
are 89% and 86%, respectively with a median follow-up of 1.3
(range, 0.1-7.6) years. The cumulative incidence of graft failure was
4%. Results after unrelated donor UCBT remain limited, but
suggest encouraging results, particularly with regard to the rates of
acute and chronic GVHD. UCBT in lieu of more conventional
sources of hematopoietic cells may be particularly advantageous when
there is urgency for transplantation and in non-malignant disorders
where GVHD, in particular, has a negative impact upon outcome.
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UNRELATED CORD BLOOD TRANSPLANTATION (CBT) FOR HEMOGLO-
BINOPATHY
Jaing, Tang-Her,1 Tan, Patrick,2 Rosenthal, Joseph,3 Wang, Brian,4
Gjertson, David,4,5 Petz, Lawrence D.,5,6 Chow, Robert.6,7,8 1Chang
Gung University & Children’s Hospital, Linko, Taiwan; 2Haematology
& Stem Cell Transplant Center, Mount Elizabeth Hospital, Singapore;
3City of Hope National Medical Center, Duarte, CA; 4UCLA School of
Public Health and 5UCLA Medical Center, Los Angeles, CA; 6StemCyte
International Cord Blood Center, Arcadia, CA; 7StemCyte Taiwan
National Cord Blood Center, Linko, Taiwan; 8StemCyte Research In-
stitute, Arcadia, CA.
Unrelated umbilical cord blood transplantation (CBT) is a po-
tentially curative therapy for most hemoglobinopathy patients;
however, cell dosage is a critical factor for CBT. We previously
showed that by combining strategies that maximize cell dose, that
is, non-red cell reduced plasma depleted cord blood (PD CB),
forego post-thaw wash, and double cord blood transplantation
when needed—promising results may be achieved with unrelated
CBT in selected patients (Jaing et al, BBMT 2005;11:349). Be-
tween July 1991 and April 2006, 45 unrelated CBT were per-
formed after myeloablative therapy in 38 pediatric patients with
transfusion-dependent hemoglobinopathy (36 thalassemia and 2
SCD) at the authors’ institutions and 11 other centers using mostly
PDCB units that were not washed after thawing (6 double cords
and 1 re-transplant). Nineteen patients were Pesaro class 1, four
class 2, and one class 3, with 14 status unknown. The median age
of patients was 6 years old (range 0.3-20 yr) with a median weight
of 19 kg (range 8-76 kg). All PD CB data were audited internally
and externally and the primary data for the 15 patients at Chang
Gung were audited by one of the authors (JR).
No signiﬁcant adverse events were observed after direct infusion
despite major ABO incompatibility in 9 cases.
Unadjusted ANC 500 and platelet 20,000 engraftment cumulative
incidence with donor chimerism was achieved in 81  7% and 79 
8% of the cases, and median times to ANC500 engraftment, and
platelet 20,000 engraftment were 17 (range 11-33 days) and 37 (range
16-133 days) days after transplantation, respectively (Table 4).
Eight patients died with 3 deaths unrelated to the CBU (2 early
deaths prior to day 20 and one accident). All remaining 30 patients
Table 4. Summary of Clinical Outcome Based on Experience and Washing
Autologous
Recovery 1 Yr. OS
1 Yr.
DFS
Unadjusted Cumulative Incidence
III-IV aGVHD
Extensive
cGVHDANC500 Plt20K Plt50K
Less experienced 15% 63% 45% 71% 56% 56% 0% 0%
Experienced 11% 87% 77% 87% 86% 86% 16% 10%
Not Washed 12% 83% 72% 83% 86% 82% 13% 8%
Washed 17% 55% 26% 70% 40% 40% 0% 0%
Overall 13  6% 77  7% 65  8% 81  7% 79  8% 76  8% 11% 6%
Table 5. Summary of Graft Parameters Based on Experience and Washing
Patients,
n
CBU,
n
HLA
Matches, n
Prefreeze
TNC Dose
Post-thaw
TNC Dose
TNC
Recovery
Prefreeze
CD34 Dose
Post-thaw
CD34 Dose
CD34 Cell
Recovery
Less experienced 15 15 5.0 6.8 2.6 83% 3.6 1.1 39%
Experienced 23 30 4.0 8.9 6.6 89% 3.4 3.3 99%
Not washed 31 38 4.0 9.1 5.6 81% 3.5 2.9 83%
Washed 7 7 5.0 6.4 2.1 NA 3.9 3.1 NA
Overall 38 45 4.0 8.1 5.6 82% 3.4 2.9 84%
Table 3. Interaction between HLA Mismatches, Number of Cells and
Outcomes in Unrelated Cord Blood Transplants for Non-Malignant
Diseases
Number of
HLA MM 0-1
vs 2 vs 3-4
Type of
HLA MM
Class I vs II
Interaction with
Number of Cells
PMN engraftment Less More 2 DRB1  Less <cells and >MM
Platelet engraftment Less More 2 DRB1  Less <cells and >MM
TRM More Less 2 DRB1  Less <cells and >MM
AGVHD More Same More >cells and >MM
CGVHD More Same More >cells and >MM
LFS, OS Less Better 2 DRB1  Worse if HLA MM >2 and
NC <3.5 NC/kg
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